208 related articles for article (PubMed ID: 23821043)
1. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
Maegdefessel L; Buerke M; Schubert S; Reindl I; Michel T; Hauroeder B; Carter JM; Peetz D; Werdan K; Schlitt A
Thromb Haemost; 2008 Oct; 100(4):693-8. PubMed ID: 18841294
[TBL] [Abstract][Full Text] [Related]
3. In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.
Schlitt A; Rupprecht HJ; Reindl I; Schubert S; Hauroeder B; Carter JM; Peetz D; Kropff SS; Maegdefessel L; Russ M; Schmidt H; Ebelt H; Werdan K; Buerke M
Coron Artery Dis; 2008 Jun; 19(4):279-84. PubMed ID: 18480673
[TBL] [Abstract][Full Text] [Related]
4. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo.
Yau JW; Stafford AR; Liao P; Fredenburgh JC; Roberts R; Weitz JI
Blood; 2011 Dec; 118(25):6667-74. PubMed ID: 21937693
[TBL] [Abstract][Full Text] [Related]
6. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
7. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
[TBL] [Abstract][Full Text] [Related]
8. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
9. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.
Schlitt A; Buerke M; Hauroeder B; Peetz D; Hundt F; Bickel C; Schaefer I; Meyer J; Rupprecht HJ
Thromb Haemost; 2003 Aug; 90(2):245-51. PubMed ID: 12888871
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
[TBL] [Abstract][Full Text] [Related]
12. Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study.
Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
J Thromb Haemost; 2017 Jan; 15(1):38-46. PubMed ID: 27736032
[TBL] [Abstract][Full Text] [Related]
13. Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
Kalaska B; Kaminski K; Miklosz J; Yusa SI; Sokolowska E; Blazejczyk A; Wietrzyk J; Kasacka I; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
Transl Res; 2016 Nov; 177():98-112.e10. PubMed ID: 27456749
[TBL] [Abstract][Full Text] [Related]
14. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.
Raaz U; Buerke M; Busshardt M; Maegdefessel L; Plehn A; Hauroeder B; Werdan K; Schlitt A
J Thromb Thrombolysis; 2010 Apr; 29(3):265-70. PubMed ID: 19517216
[TBL] [Abstract][Full Text] [Related]
16. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
17. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
[TBL] [Abstract][Full Text] [Related]
18. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
Matziolis G; Perka C; Disch A; Zippel H
Calcif Tissue Int; 2003 Oct; 73(4):370-9. PubMed ID: 12874702
[TBL] [Abstract][Full Text] [Related]
19. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
20. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
